Asbestos Mesothelioma Mesothelioma Treatment News About ELSS Top Mesothelioma Doctors

Dr. David Sugarbaker
Boston, MA; Pioneered the "tri-modal" approach to treating malignant pleural mesothelioma...

Dr. Robert N. Taub
New York, NY; Prominent mesothelioma doctor and director of Columbia’s Mesothelioma Center...

Enter your information to receive a comprehensive mesothelioma packet free of charge at your doorstep within 24 hours.

First Name:

Last Name:

Address:

City:

ST:

Zip:

Home Phone:

Work Phone:

Cell Phone:

Email Address:

Have you or someone you know been diagnosed with mesothelioma?

Yes   No

Mesothelioma Treatment | Leading Physicians

Dr. Robert N. Taub – New York-Presbyterian/Columbia

Professional Highlights

Dr. Robert N. Taub – New York-Presbyterian/Columbia

Dr. Robert Taub serves as director of Columbia’s Mesothelioma Center, where he is developing combined chemotherapeutic and surgical techniques that are highly effective in combating Mesothelioma, an often fatal disease. His work has been recognized and awarded by the Israel Cancer Research Fund, the Mount Sinai Hospital, and the American Cancer Society. His career has spanned medical oncology, immunology, hematology, and internal medicine.

Educational Background and Professional Appointments

Dr. Taub received his medical degree from the Yale University School of Medicine, where he was later made a fellow. His internship was completed at the New England Medical Center – TUFTS University. He is board certified in Oncology, Internal Medicine, Hematology, and Allergy & Immunology.

Dr. Robert N. Taub, M.D., Ph.D. was recently appointed to the chair of Medicine at Columbia University Medical Center. There, he serves as a mentor to aspiring oncologists, stressing multidisciplinary approaches to mesothelioma treatment.

Relevant Articles by Dr. Robert N. Taub

Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas.

P16 loss and mitotic activity predict poor survival in patients with peritoneal malignant mesothelioma.

High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.

Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma.

If you have any questions regarding treatment options or your legal rights, please contact us.